embibatinib   Click here for help

GtoPdb Ligand ID: 14354

Synonyms: example 5 [US10889571B2] | HS-10382 | TERN-701
Compound class: Synthetic organic
Comment: This compound is an allosteric ABL kinase inhibitor that was developed for antineoplastic activity in BCR::ABL1 fusion positive myeloma [2]. It binds the ABL myristoyl pocket. The chemical structure was obtained from WHO proposed list 134 (Feb 2026), and matched to an example in patent US10889571B2. Predicted to be Terns Pharmaceuticals' allosteric
 BCR-ABL inhibitor TERN-701.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 98.88
Molecular weight 523.87
XLogP 1.92
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@H](CO)N1C2=C(C=C(C=C2C3=CN=CN=C3)C(=O)NC4=CC=C(C=C4)OC(Cl)(F)F)N=C1C(F)F
Isomeric SMILES C[C@H](CO)N1C2=C(C=C(C=C2N=C1C(F)F)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CN=CN=C4
InChI InChI=1S/C23H18ClF4N5O3/c1-12(10-34)33-19-17(14-8-29-11-30-9-14)6-13(7-18(19)32-21(33)20(25)26)22(35)31-15-2-4-16(5-3-15)36-23(24,27)28/h2-9,11-12,20,34H,10H2,1H3,(H,31,35)/t12-/m1/s1
InChI Key MTFOIMMCUOJPHL-GFCCVEGCSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
TERN-701 has advanced to clinical trials to evaluate safety and determine efficacy in the treatment of chronic myeloid leukemia.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06163430 A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) Phase 1/Phase 2 Interventional Terns, Inc.